Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults

OBJECTIVES: We investigated the safety, tolerability, pharmacokinetics and pharmacodynamics of evacetrapib. METHODS: Healthy volunteers received multiple daily doses of evacetrapib (10–600 mg) administered for up to 15 days in a placebo-controlled study. KEY FINDINGS: Mean peak plasma concentrations...

Descripción completa

Detalles Bibliográficos
Autores principales: Suico, Jeffrey G, Wang, Ming-Dauh, Friedrich, Stuart, Cannady, Ellen A, Konkoy, Christopher S, Ruotolo, Giacomo, Krueger, Kathryn A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Ltd 2014
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284021/
https://www.ncbi.nlm.nih.gov/pubmed/24961753
http://dx.doi.org/10.1111/jphp.12287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284021/
https://www.ncbi.nlm.nih.gov/pubmed/24961753
http://dx.doi.org/10.1111/jphp.12287

Ejemplares similares